Title
Subscribe to the Magazine for free
Subscribe for free to keep reading! If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.

Systemic Treatments for Psoriasis: Oral and Injectable Options

Written By

Why This Was Updated?

Our specialists regularly review advancements in health and wellness, ensuring our articles are updated with the newest information as it becomes accessible.
Medically Reviewed by
Dr.
Ayesha Bryant
MSPH, MD

Psoriasis is a chronic autoimmune condition that leads to inflammation and the rapid turnover of skin cells, resulting in the formation of red, scaly patches. Managing severe cases of psoriasis often requires systemic interventions rather than just topical treatments or phototherapy. 

Systemic treatments, including oral and injectable medications, target the underlying immune dysfunction to provide comprehensive disease control. This article provides an overview of the various systemic treatment options, including their mechanisms of action, benefits, and potential side effects.

[signup]

Understanding Systemic Treatments

Systemic treatments are medications that work throughout the body instead of topical treatments or phototherapy, which act locally on the skin. These therapies target the underlying immune dysfunction in psoriasis, providing a more comprehensive approach by suppressing the immune response or correcting abnormal cell turnover.

Systemic treatments are typically prescribed for individuals with moderate to severe psoriasis or psoriatic arthritis, especially when other therapies have not been effective. They are also considered in cases where psoriasis significantly impairs the quality of life and daily functioning or involves large body surface areas.

The primary goals of systemic therapy include reducing inflammation, slowing down the rapid overproduction of skin cells, and managing the symptoms associated with psoriasis. By addressing these key aspects, systemic treatments aim to achieve clearer skin, improve joint symptoms in psoriatic arthritis, and ultimately enhance overall disease control.

Oral Systemic Treatments for Psoriasis

Oral systemic treatments target psoriasis from within the body, offering solutions for moderate to severe cases. Here's a look at key options, their mechanisms, and potential side effects.

1. Methotrexate

  • Mechanism of Action: Methotrexate works by inhibiting the enzyme dihydrofolate reductase, which is essential for DNA synthesis and cell replication. This action suppresses the immune system and reduces inflammation, leading to a decrease in psoriasis symptoms.
  • Usage: It is commonly used to treat moderate to severe psoriasis and psoriatic arthritis, particularly when patients do not respond to topical treatments alone.
  • Benefits: Methotrexate effectively reduces symptoms and improves the appearance of the skin, often leading to significant improvements in disease activity.
  • Side Effects: Potential side effects include liver toxicity, nausea, and fatigue, making regular monitoring essential, especially with long-term use.

2. Cyclosporine

  • Mechanism of Action: Cyclosporine suppresses the immune system by inhibiting the activation of T-cells, which are involved in the inflammatory process of psoriasis.
  • Usage: Due to its rapid symptom-reducing effects, it is typically prescribed for short-term use, particularly during flare-ups of severe psoriasis.
  • Benefits: Cyclosporine quickly reduces symptoms, making it especially useful in severe or acute cases.
  • Side Effects: Risks include kidney damage and high blood pressure, necessitating careful monitoring during treatment, especially with prolonged use.

3. Acitretin

  • Mechanism of Action: Acitretin is a retinoid that helps to normalize skin cell growth and differentiation, making it particularly useful in certain forms of psoriasis.
  • Usage: It is often used in pustular or erythrodermic psoriasis cases and can be combined with other therapies for enhanced effectiveness.
  • Benefits: Acitretin is effective in specific types of psoriasis, offering a unique mechanism that complements other systemic options.
  • Side Effects: Potential side effects include dry skin, hair loss, and teratogenicity, which require careful patient selection and counseling regarding the risks.

4. Apremilast

  • Mechanism of Action: Apremilast inhibits the enzyme phosphodiesterase 4 (PDE4), which plays a key role in the inflammatory process. Thus, it reduces inflammation and the severity of psoriasis symptoms.
  • Usage: It is indicated for moderate to severe plaque psoriasis and psoriatic arthritis, particularly for those seeking an oral option with a different mechanism of action compared to traditional immunosuppressants.
  • Benefits: Apremilast offers a favorable safety profile, making it a valuable option for patients who may not tolerate other systemic treatments well.
  • Side Effects: Possible side effects include gastrointestinal issues and mood changes, highlighting the need for ongoing monitoring and patient education during treatment.

Injectable Systemic Treatments for Psoriasis (Biologics)

Injectable biologics target specific immune pathways, offering effective options for managing moderate to severe psoriasis. Here’s a look at key biologics, their uses, and potential side effects.

1. Tumor Necrosis Factor (TNF) Inhibitors

  • Examples: Etanercept, Infliximab, Adalimumab.
  • Mechanism of Action: TNF inhibitors block the inflammatory cytokine TNF-alpha, which plays akey role in the inflammatory process of psoriasis. By inhibiting TNF-alpha, these biologics help reduce inflammation and slow disease progression.
  • Usage: These agents are indicated for moderate to severe psoriasis and psoriatic arthritis, especially in cases where traditional systemic treatments are insufficient.
  • Benefits: TNF inhibitors are highly effective in reducing psoriasis symptoms and improving joint health, offering significant relief for those with psoriatic arthritis.
  • Side Effects: Potential risks include increased susceptibility to infections, necessitating regular monitoring, and caution in patients with recurrent infections.

2. Interleukin (IL) Inhibitors

  • Examples: Ustekinumab (IL-12/23 inhibitor), Secukinumab (IL-17A inhibitor), Ixekizumab (IL-17A inhibitor), Guselkumab (IL-23 inhibitor).
  • Mechanism of Action: IL inhibitors target specific interleukins—key signaling molecules in the inflammatory cascade of psoriasis. By blocking these interleukins, IL inhibitors provide targeted control of inflammation and reduce skin lesions.
  • Usage: IL inhibitors are typically prescribed for moderate to severe psoriasis, particularly in patients who have not responded adequately to other treatments.
  • Benefits: These biologics offer a targeted approach with high efficacy in reducing both skin lesions and systemic inflammation. They provide a focused, therapeutic option with fewer systemic effects compared to broader immunosuppressants.
  • Side Effects: Potential side effects include an increased risk of infections and possible long-term impacts on the immune system, highlighting the need for careful patient monitoring.

3. T-Cell Inhibitors

  • Example: Alefacept (no longer commonly used).
  • Mechanism of Action: T-cell inhibitors reduce the activity of T-cells, which play a central role in the pathogenesis of psoriasis. By targeting these immune cells, T-cell inhibitors help modulate the immune response and control disease activity.
  • Usage: Historically, T-cell inhibitors like Alefacept were used to manage psoriasis, but their use has declined in favor of newer, more effective biologics.
  • Benefits: These treatments provided a specific approach to targeting immune cells directly involved in psoriasis.
  • Side Effects: Safety concerns, such as increased risk of infections and variable efficacy, have led to a shift towards other biologic therapies that offer more consistent results and a better safety profile.

Choosing the Right Systemic Treatment

Selecting the appropriate systemic treatment for psoriasis involves carefully evaluating several factors to tailor the therapy to the patient's needs and circumstances.

Factors Influencing Treatment Choice

  • Severity of Psoriasis: Systemic treatments are typically reserved for moderate to severe cases of psoriasis, where the skin surface affected is extensive or when the condition significantly impacts the patient's quality of life.
  • Presence of Psoriatic Arthritis: Patients with joint involvement often require systemic treatments that address skin and joint symptoms, such as TNF or interleukin inhibitors.
  • Patient Preference: Patient preferences, including the mode of administration (oral vs. injectable), dosing frequency, and potential side effects, play a crucial role in treatment selection. Understanding patient preferences can improve adherence and satisfaction with the treatment.
  • Comorbidities: The presence of other health conditions, such as cardiovascular disease, diabetes, or liver issues, may influence the choice of systemic therapy due to potential drug interactions and side effects.

Weighing Benefits Against Risks

Systemic treatments offer significant benefits in managing psoriasis symptoms and improving quality of life, but they also carry potential risks. These treatments often suppress the immune system, increasing the risk of infections and other side effects such as liver or kidney damage. 

It is essential to balance these benefits and risks through a thorough discussion with healthcare providers, considering the patient's health status and treatment goals.

Managing Side Effects and Long-Term Care

Systemic treatments can come with a range of side effects, from mild to severe. Regular monitoring helps identify these early, allowing for prompt management and minimizing the impact on overall treatment success. 

Skipping doses or inconsistent use can reduce the effectiveness of the therapy and may lead to worsening of symptoms. Treatment plans may need adjustments over time based on patient response, side effects development, or disease severity changes. Flexibility in managing these therapies ensures that patients receive the most effective and safe treatment over the long term.

Regular communication with healthcare providers is vital for ongoing care. This partnership helps ensure that any concerns or side effects are promptly addressed and that the treatment plan continues to align with the patient’s needs and health status.

[signup]

Key Takeaways

  • Systemic treatments target the underlying immune dysfunction in moderate to severe psoriasis, offering more comprehensive control than topical or phototherapy options.
  • Oral systemic treatments, such as methotrexate, cyclosporine, acitretin, and apremilast, work by suppressing the immune system, reducing inflammation, and normalizing skin cell turnover. However, they come with potential side effects like liver toxicity, kidney damage, and gastrointestinal issues.
  • Injectable biologics, including TNF inhibitors and interleukin inhibitors, provide targeted immune pathway intervention, effectively reducing psoriasis symptoms and inflammation. However, they also carry risks, such as increased susceptibility to infections.
  • Selecting the right systemic treatment involves considering the severity of psoriasis, the presence of psoriatic arthritis, patient preferences, and comorbidities, balancing benefits against potential risks.
  • Long-term management requires regular monitoring and adjustments to treatment plans to manage side effects and ensure the most effective and safe therapy tailored to the patient’s evolving needs.
The information provided is not intended to be a substitute for professional medical advice. Always consult with your doctor or other qualified healthcare provider before taking any dietary supplement or making any changes to your diet or exercise routine.
Learn More
No items found.

Lab Tests in This Article

No lab tests!

Agüero, R., Woodbury, M. J., Lee, K., Johnsson, H., Merola, J. F., & Armstrong, A. W. (2023). Interleukin (IL)-17 Versus IL-23 Inhibitors: Which Is Better to Treat Patients With Moderate-to-Severe Psoriasis and Mild Psoriatic Arthritis in Dermatology Clinics? The Journal of Rheumatology, jrheum.2023-0511. https://doi.org/10.3899/jrheum.2023-0511

Armstrong, A. W., Sayeli Jayade, Rege, S., Joshi, N., Patel, V., Samaneh Kalirai, Wolin, D., Boyle, K., Patel, D., & Seigel, L. (2024). Evaluating Treatment Choice in Patients with Moderate to Severe Psoriasis in the United States: Results from a US Patient Survey. Dermatology and Therapy, 14(2), 421–439. https://doi.org/10.1007/s13555-023-01089-6

Balak, D. M. W., Gerdes, S., Parodi, A., & Salgado-Boquete, L. (2020). Long-term Safety of Oral Systemic Therapies for Psoriasis: A Comprehensive Review of the Literature. Dermatology and Therapy, 10(4), 589–613. https://doi.org/10.1007/s13555-020-00409-4

Belanger, B. G., & Lui, F. (2021). Embryology, Teratology TORCH. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK545148/

Belinchón Romero, I., Dauden, E., Ferrándiz Foraster, C., González-Cantero, Á., & Carrascosa Carrillo, J. M. (2021). Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document. Annals of Medicine, 53(1), 1727–1736. https://doi.org/10.1080/07853890.2021.1986637

Brownstone, N. D., Hong, J., Mosca, M., Hadeler, E., Liao, W., Bhutani, T., & Koo, J. (2021). Biologic Treatments of Psoriasis: An Update for the Clinician. Biologics : Targets & Therapy, 15, 39–51. https://doi.org/10.2147/BTT.S252578

Campbell, K., Li, K., Yang, F., Branigan, P., M Merle Elloso, Benson, J., Orlovsky, Y., Chen, Y., Garcet, S., & Krueger, J. G. (2023). Guselkumab More Effectively Neutralizes Psoriasis-Associated Histologic, Transcriptomic, and Clinical Measures than Ustekinumab. ImmunoHorizons, 7(4), 273–285. https://doi.org/10.4049/immunohorizons.2300003

Cloyd, J. (2023a, March 7). An integrative medicine approach to fatigue. Rupa Health. https://www.rupahealth.com/post/an-integrative-medicine-approach-to-fatigue

Cloyd, J. (2023b, May 18). Complementary and Integrative Medicine Approaches to Managing High Blood Pressure: Specialty Testing, Lifestyle Modifications, and Natural Remedies. Rupa Health. https://www.rupahealth.com/post/complementary-and-integrative-medicine-approaches-to-managing-high-blood-pressure-testing-lifestyle-modifications-and-natural-remedies

Cooper, K. D., Voorhees, J. J., Fisher, G. J., Chan, L. S., Gupta, A. K., & Baadsgaard, O. (1990). Effects of cyclosporine on immunologic mechanisms in psoriasis. Journal of the American Academy of Dermatology, 23(6 Pt 2), 1318–1326; discussion 1326-1328. https://doi.org/10.1016/0190-9622(90)70360-t

DeCesaris, L. (2022, June 6). What Is Gut Dysbiosis? 7 Signs To Watch For. Rupa Health. https://www.rupahealth.com/post/how-your-gut-bacteria-affects-your-overall-health

DeCesaris, L. (2023, December 12). Elevating Mood with Nutraceuticals: A Functional Medicine Perspective. Rupa Health. https://www.rupahealth.com/post/elevating-mood-with-nutraceuticals-a-functional-medicine-perspective

DePorto, T. (2022, August 17). Joint Stiffness, Psoriasis, And Fatigue Are Signs Of This Inflammatory Condition. Rupa Health. https://www.rupahealth.com/post/how-to-naturally-relieve-psoriatic-arthritis-symptoms

El-Esawy, F. M., Ahmed, I. A., El-Fallah, A. A., & Salem, R. M. (2022). Methotrexate Mechanism of Action in Plaque Psoriasis: Something New in the Old View. The Journal of Clinical and Aesthetic Dermatology, 15(8), 42–46. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436225/

Ellis, C. N., & Krueger, G. G. (2001). Treatment of Chronic Plaque Psoriasis by Selective Targeting of Memory Effector T Lymphocytes. New England Journal of Medicine, 345(4), 248–255. https://doi.org/10.1056/nejm200107263450403

Emer, J. J., Frankel, A., & Zeichner, J. A. (2010). A Practical Approach to Monitoring Patients on Biological Agents for the Treatment of Psoriasis. The Journal of Clinical and Aesthetic Dermatology, 3(8), 20–26. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945861/

Ghoreschi, K., Balato, A., Enerbäck, C., & Sabat, R. (2021). Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. The Lancet, 397(10275), 754–766. https://doi.org/10.1016/s0140-6736(21)00184-7

Gisondi, P., Del Giglio, M., & Girolomoni, G. (2017). Treatment Approaches to Moderate to Severe Psoriasis. International Journal of Molecular Sciences, 18(11). https://doi.org/10.3390/ijms18112427

Jenneck, C., & Novak, N. (2007). The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis. Therapeutics and Clinical Risk Management, 3(3), 411–420. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2386357/

Khakham, C. (2023a, March 28). An integrative medicine approach to kidney disease. Rupa Health. https://www.rupahealth.com/post/an-integrative-medicine-approach-to-kidney-disease

Khakham, C. (2023b, August 4). Top Labs To Run Bi-Annually On Your Psoriasis Patients. Rupa Health. https://www.rupahealth.com/post/top-labs-to-run-bi-annually-on-your-psoriasis-patients

Korman, N. J. (2019). Management of psoriasis as a systemic disease: what is the evidence? British Journal of Dermatology, 182(4), 840–848. https://doi.org/10.1111/bjd.18245

Martin, G., Young, M., & Aldredge, L. (2019). Recommendations for Initiating Systemic Therapy in Patients with Psoriasis. The Journal of Clinical and Aesthetic Dermatology, 12(4), 13–26. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6508485/

National Psoriasis Foundation. (n.d.). Systemic Treatments for Psoriasis and Psoriatic Arthritis. Www.psoriasis.org. https://www.psoriasis.org/systemics/

Prignano, F., Choi, J., Pieper, B., & Iversen, L. (2020). Anti-tumor necrosis factor agents in psoriasis: addressing key challenges using biosimilars. Expert Opinion on Biological Therapy, 21(1), 75–80. https://doi.org/10.1080/14712598.2020.1812576

Raychaudhuri, S. P., & Raychaudhuri, S. K. (2009). BIOLOGICS: TARGET-SPECIFIC TREATMENT OF SYSTEMIC AND CUTANEOUS AUTOIMMUNE DISEASES. Indian Journal of Dermatology, 54(2), 100–109. https://doi.org/10.4103/0019-5154.53175

Sweetnich, J. (2023, April 5). Top 5 Labs for Patients Experiencing Hair Loss. Rupa Health. https://www.rupahealth.com/post/top-5-labs-for-patients-experiencing-hair-loss

TP Afra, T Muhammed Razmi, & Sunil Dogra. (2019). Apremilast in psoriasis and beyond: Big hopes on a small molecule. Indian Dermatology Online Journal, 10(1), 1. https://doi.org/10.4103/idoj.IDOJ_437_18

Zito, P. M., & Mazzoni, T. (2020). Acitretin. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK519571/

Subscribe to the Magazine for free to keep reading!
Subscribe for free to keep reading, If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
See All Magazine Articles
Trusted Source
Rupa Health
Medical Education Platform
Visit Source
American Cancer Society
Foundation for Cancer Research
Visit Source
National Library of Medicine
Government Authority
Visit Source
Journal of The American College of Radiology
Peer Reviewed Journal
Visit Source
National Cancer Institute
Government Authority
Visit Source
World Health Organization (WHO)
Government Authority
Visit Source
The Journal of Pediatrics
Peer Reviewed Journal
Visit Source
CDC
Government Authority
Visit Source
Office of Dietary Supplements
Government Authority
Visit Source
National Heart Lung and Blood Institute
Government Authority
Visit Source
National Institutes of Health
Government Authority
Visit Source
Clinical Infectious Diseases
Peer Reviewed Journal
Visit Source
Brain
Peer Reviewed Journal
Visit Source
The Journal of Rheumatology
Peer Reviewed Journal
Visit Source
Journal of the National Cancer Institute (JNCI)
Peer Reviewed Journal
Visit Source
Journal of Cardiovascular Magnetic Resonance
Peer Reviewed Journal
Visit Source
Hepatology
Peer Reviewed Journal
Visit Source
The American Journal of Clinical Nutrition
Peer Reviewed Journal
Visit Source
The Journal of Bone and Joint Surgery
Peer Reviewed Journal
Visit Source
Kidney International
Peer Reviewed Journal
Visit Source
The Journal of Allergy and Clinical Immunology
Peer Reviewed Journal
Visit Source
Annals of Surgery
Peer Reviewed Journal
Visit Source
The Journal of Neurology, Neurosurgery & Psychiatry
Peer Reviewed Journal
Visit Source
Chest
Peer Reviewed Journal
Visit Source
Blood
Peer Reviewed Journal
Visit Source
Gastroenterology
Peer Reviewed Journal
Visit Source
The American Journal of Respiratory and Critical Care Medicine
Peer Reviewed Journal
Visit Source
The American Journal of Psychiatry
Peer Reviewed Journal
Visit Source
Diabetes Care
Peer Reviewed Journal
Visit Source
The Journal of the American College of Cardiology (JACC)
Peer Reviewed Journal
Visit Source
The Journal of Clinical Oncology (JCO)
Peer Reviewed Journal
Visit Source
Journal of Clinical Investigation (JCI)
Peer Reviewed Journal
Visit Source
Circulation
Peer Reviewed Journal
Visit Source
JAMA Internal Medicine
Peer Reviewed Journal
Visit Source
PLOS Medicine
Peer Reviewed Journal
Visit Source
Annals of Internal Medicine
Peer Reviewed Journal
Visit Source
Nature Medicine
Peer Reviewed Journal
Visit Source
The BMJ (British Medical Journal)
Peer Reviewed Journal
Visit Source
The Lancet
Peer Reviewed Journal
Visit Source
Journal of the American Medical Association (JAMA)
Peer Reviewed Journal
Visit Source
Pubmed
Comprehensive biomedical database
Visit Source
Harvard
Educational/Medical Institution
Visit Source
Cleveland Clinic
Educational/Medical Institution
Visit Source
Mayo Clinic
Educational/Medical Institution
Visit Source
The New England Journal of Medicine (NEJM)
Peer Reviewed Journal
Visit Source
Johns Hopkins
Educational/Medical Institution
Visit Source